~~<i id='B8F9219C9B'><strike id='B8F9219C9B'><tt id='B8F9219C9B'><pre id='B8F9219C9B'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

focus

Wikipedia

author：fashion 2025-08-28 13:04:15 - browse：71218

Roche’s announcement Monday that it would pay $310 million for rights to a hypertension treatment, zilebesiran, invented by the biotech firm Alnylam is evidence of a renewed interest on the part of large pharmaceutical companies for treatments for cardiovascular disease.

If things go well, Roche could pay Alnylam up to $2.8 billion in total.

Heart drugs were once the most lucrative category of pharmaceuticals, but they have been eclipsed by treatments for cancer and other diseases as drug firms have struggled to one-up existing treatments for high blood pressure and high cholesterol that are now available as cheap generics.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Duchenne breakthrough therapy leaves behind pioneering families
Next article： Poor hospice wound care hurts patients and families

hotspot

knowledge

hotspot

entertainment

knowledge

entertainment

KenaBetancur/GettyImagesWanttostayontopofthescienceandpoliticsdrivingbiotechtoday? Signup togetourbi

WSS

Lack of darker skin in textbooks, journals harms patients of color

Ransomware attacks on hospitals: Study outlines patient impact

Readout Newsletter: Bayer study halts, Carmot to IPO, and more

Surge of respiratory disease in China has likely explanation

US soldier in North Korean custody after crossing DMZ line

Hospitals look to new technology to keep health care workers safe

focus

Wikipedia

hotspot

Activists slam private health insurers over coverage restrictions

Congress must reauthorize a committee to support older Americans

Apple is now the first public company to be valued at $3 trillion

World's first CRISPR

In age of alternative facts, a scholarly course on calling out crap

Israeli protesters block highways, train stations as Netanyahu moves ahead with judicial overhaul

New air purifier tech could be key to improving indoor air quality

UK homeowners get some respite as inflation falls by more than anticipated to a 15

ChatGPT in medicine: STAT answers readers' burning questions

FDA's Woodcock to retire early next year

knowledge

Anthos stroke drug appears safer than common blood thinner

Ford plant in Missouri shuts down over 'possible threat,' sheriff's office says

Britain’s MI6 chief says his spies are using AI to disrupt flow of weapons to Russia

CRISPR pioneers react to Casgevy, first gene

Ransomware attacks on hospitals: Study outlines patient impact

Study: Hearing aids may slow cognitive decline in those at risk

hotspot

entertainment

knowledge

entertainment